Display options
Cite
Wang S, Meng Y, Li C, et al. Receptor-Mediated Drug Delivery Systems Targeting to Glioma. Nanomaterials (Basel). 2015;6(1)doi: 10.3390/nano6010003.
Wang, S., Meng, Y., Li, C., Qian, M., & Huang, R. (2015). Receptor-Mediated Drug Delivery Systems Targeting to Glioma. Nanomaterials (Basel, Switzerland), 6(1), . https://doi.org/10.3390/nano6010003
Wang, Shanshan, et al. "Receptor-Mediated Drug Delivery Systems Targeting to Glioma." Nanomaterials (Basel, Switzerland) vol. 6,1 (2015). doi: https://doi.org/10.3390/nano6010003
Wang S, Meng Y, Li C, Qian M, Huang R. Receptor-Mediated Drug Delivery Systems Targeting to Glioma. Nanomaterials (Basel). 2015 Dec 28;6(1). doi: 10.3390/nano6010003. PMID: 28344260; PMCID: PMC5302535.
Copy Download .nbib Format: NLM
Share it on

Nanomaterials (Basel). 2015 Dec 28;6(1). doi: 10.3390/nano6010003.

Receptor-Mediated Drug Delivery Systems Targeting to Glioma.

Nanomaterials (Basel, Switzerland)

Shanshan Wang, Ying Meng, Chengyi Li, Min Qian, Rongqin Huang

Affiliations

  1. Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, China. [email protected].
  2. Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, China. [email protected].
  3. Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, China. [email protected].
  4. Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, China. [email protected].
  5. Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, China. [email protected].

PMID: 28344260 PMCID: PMC5302535 DOI: 10.3390/nano6010003

Abstract

Glioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radiotherapy, and chemotherapy. This provides a rationale for the development of some novel therapeutic strategies. Among them, receptor-mediated drug delivery is a specific pattern taking advantage of differential expression of receptors between tumors and normal tissues. The strategy can actively transport drugs, such as small molecular drugs, gene medicines, and therapeutic proteins to glioma while minimizing adverse reactions. This review will summarize recent progress on receptor-mediated drug delivery systems targeting to glioma, and conclude the challenges and prospects of receptor-mediated glioma-targeted therapy for future applications.

Keywords: blood-brain barrier (BBB); dual ligand-modified targeting systems; glioma; receptor-mediated; single ligand-modified targeting systems

References

  1. Eur J Pharm Sci. 2013 Jul 16;49(4):556-64 - PubMed
  2. Clin Cancer Res. 2013 Mar 15;19(6):1567-76 - PubMed
  3. Hepatogastroenterology. 2014 Mar-Apr;61(130):426-30 - PubMed
  4. PLoS One. 2011;6(12):e28881 - PubMed
  5. Fish Shellfish Immunol. 2011 Dec;31(6):1154-61 - PubMed
  6. Biomaterials. 2007 Nov;28(33):4947-67 - PubMed
  7. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7594-9 - PubMed
  8. J Biomed Sci. 2015 Jul 08;22:51 - PubMed
  9. Br J Cancer. 2011 Nov 22;105(11):1697-707 - PubMed
  10. Clin Pharmacol Ther. 2015 Apr;97(4):336-46 - PubMed
  11. Nat Rev Cancer. 2002 Feb;2(2):91-100 - PubMed
  12. BMC Cancer. 2011 Aug 18;11:359 - PubMed
  13. Biomaterials. 2012 May;33(15):3899-908 - PubMed
  14. PLoS One. 2008 Jun 25;3(6):e2469 - PubMed
  15. Int J Clin Exp Med. 2015 Feb 15;8(2):1658-68 - PubMed
  16. J Gene Med. 2002 Mar-Apr;4(2):183-94 - PubMed
  17. Int J Pharm. 2014 Oct 1;473(1-2):334-44 - PubMed
  18. Int J Pharm. 2015 Jul 5;488(1-2):165-73 - PubMed
  19. Mol Pharm. 2014 Mar 3;11(3):1042-52 - PubMed
  20. Neurosurg Focus. 2015 Mar;38(3):E9 - PubMed
  21. J Pharm Sci. 2014 Dec;103(12):3891-901 - PubMed
  22. Biomaterials. 2013 Nov;34(33):8511-20 - PubMed
  23. Arch Pharm Res. 2014 Dec;37(12 ):1546-53 - PubMed
  24. Mol Cancer Ther. 2008 Jun;7(6):1579-87 - PubMed
  25. ACS Appl Mater Interfaces. 2014 Nov 26;6(22):19850-7 - PubMed
  26. J Vet Med Sci. 2003 Sep;65(9):957-64 - PubMed
  27. J Cell Sci. 2004 Oct 1;117(Pt 21):5071-8 - PubMed
  28. Mol Pharmacol. 2011 Jul;80(1):32-9 - PubMed
  29. Cancer Res. 2015 Apr 1;75(7):1356-65 - PubMed
  30. J Control Release. 2013 Dec 28;172(3):921-8 - PubMed
  31. Nat Rev Neurosci. 2006 Jan;7(1):41-53 - PubMed
  32. J Control Release. 2015 Apr 28;204:60-9 - PubMed
  33. Biomaterials. 2012 Feb;33(4):1170-9 - PubMed
  34. J Biomed Sci. 2007 Jan;14(1):121-8 - PubMed
  35. J Neurochem. 2008 Aug;106(4):1534-44 - PubMed
  36. Biomaterials. 2012 Nov;33(32):8167-76 - PubMed
  37. J Am Chem Soc. 2013 Mar 27;135(12):4799-804 - PubMed
  38. J Drug Target. 2006 May;14(4):191-214 - PubMed
  39. Biomaterials. 2014 Jul;35(22):5897-907 - PubMed
  40. Pharmacol Ther. 2015 Aug;152:63-82 - PubMed
  41. Mol Cancer. 2014 Aug 13;13:191 - PubMed
  42. J Pharmacol Exp Ther. 1992 Nov;263(2):897-903 - PubMed
  43. Neuro Oncol. 2014 Oct;16(10):1304-12 - PubMed
  44. J Control Release. 2007 Dec 20;124(3):163-71 - PubMed
  45. Cancer Chemother Pharmacol. 2013 Mar;71(3):799-807 - PubMed
  46. Adv Healthc Mater. 2014 Aug;3(8):1250-60 - PubMed
  47. Nat Rev Immunol. 2015 Aug;15(8):500-10 - PubMed
  48. Biomaterials. 2011 Nov;32(33):8669-75 - PubMed
  49. Macromol Biosci. 2012 Sep;12(9):1209-19 - PubMed
  50. J Neuropathol Exp Neurol. 2013 Feb;72(2):106-18 - PubMed
  51. Mol Pharm. 2014 Jan 6;11(1):90-101 - PubMed
  52. Environ Res. 2015 Jan;136:253-63 - PubMed
  53. Arch Immunol Ther Exp (Warsz). 2013 Feb;61(1):25-41 - PubMed
  54. Biomaterials. 2014 Apr;35(13):4066-81 - PubMed
  55. Curr Pharm Biotechnol. 2012 Sep;13(12):2380-7 - PubMed
  56. Biotechnol Prog. 2005 Jul-Aug;21(4):1262-8 - PubMed
  57. Mol Pharm. 2015 May 4;12(5):1467-76 - PubMed
  58. Biomaterials. 2008 Jan;29(2):238-46 - PubMed
  59. Mol Pharm. 2014 Jun 2;11(6):1823-34 - PubMed
  60. Theranostics. 2015 Apr 06;5(8):787-95 - PubMed
  61. Biomaterials. 2012 Jun;33(19):4907-16 - PubMed
  62. Nanoscale. 2015 Feb 7;7(5):1782-90 - PubMed
  63. Life Sci. 2001 Dec 21;70(5):591-601 - PubMed
  64. Biomaterials. 2011 Apr;32(11):2989-98 - PubMed
  65. J Cereb Blood Flow Metab. 2007 May;27(5):909-18 - PubMed
  66. J Biol Chem. 1999 Mar 12;274(11):7011-7 - PubMed
  67. Mol Pharm. 2014 Jul 7;11(7):2346-57 - PubMed
  68. J Nucl Med. 2014 Aug;55(8):1323-9 - PubMed
  69. Biomaterials. 2013 Jan;34(3):794-806 - PubMed
  70. J Control Release. 2002 Apr 23;80(1-3):29-44 - PubMed
  71. Oncotarget. 2014 Aug 15;5(15):6497-511 - PubMed
  72. Drug Deliv. 2015 Feb;22(2):199-205 - PubMed
  73. Cancer Lett. 2015 Jun 28;362(1):1-7 - PubMed
  74. ACS Appl Mater Interfaces. 2013 Aug 14;5(15):6909-14 - PubMed
  75. Cancer Res. 2002 Sep 15;62(18):5139-43 - PubMed
  76. J Control Release. 2015 Aug 10;211:53-62 - PubMed
  77. Int J Biol Macromol. 2015 Aug;79:669-73 - PubMed
  78. Biochim Biophys Acta. 2012 Mar;1820(3):291-317 - PubMed
  79. PLoS One. 2012;7(2):e31070 - PubMed
  80. Int J Pharm. 2013 Sep 15;454(1):11-20 - PubMed
  81. Neurobiol Dis. 2010 Jan;37(1):48-57 - PubMed
  82. J Pharmacol Exp Ther. 2008 Mar;324(3):1064-72 - PubMed
  83. Biomaterials. 2011 Jan;32(2):495-502 - PubMed
  84. Biochim Biophys Acta. 2012 Mar;1820(3):237-43 - PubMed
  85. Annu Rev Pharmacol Toxicol. 2007;47:323-55 - PubMed
  86. Nanoscale. 2014 Mar 21;6(6):3250-8 - PubMed
  87. Expert Opin Ther Targets. 2015 ;19(8):1059-72 - PubMed
  88. Drug Discov Today. 2001 Jan 1;6(1):44-51 - PubMed
  89. Neuroimaging Clin N Am. 2002 Nov;12(4):583-97 - PubMed
  90. Biometals. 2004 Jun;17(3):301-9 - PubMed
  91. Biomaterials. 2012 Jul;33(20):5115-23 - PubMed
  92. Biomaterials. 2011 Jan;32(2):478-87 - PubMed
  93. Eur J Immunol. 2013 Jan;43(1):170-81 - PubMed
  94. Biomaterials. 2014 Jun;35(19):5226-39 - PubMed
  95. Biomaterials. 2015 Jan;37:425-35 - PubMed
  96. Nanoscale. 2015 Jan 14;7(2):415-20 - PubMed
  97. Colloids Surf B Biointerfaces. 2015 Feb 1;126:414-25 - PubMed
  98. Drug Resist Updat. 2015 Mar;19:1-12 - PubMed
  99. Blood. 2015 Apr 30;125(18):2798-805 - PubMed
  100. Braz J Med Biol Res. 2012 Jun;45(6):557-64 - PubMed
  101. N Engl J Med. 2005 Mar 10;352(10 ):987-96 - PubMed
  102. Acta Neuropathol. 2006 Oct;112(4):405-15 - PubMed
  103. Biomaterials. 2013 Dec;34(36):9171-82 - PubMed
  104. Clinics (Sao Paulo). 2012;67(4):347-53 - PubMed
  105. Proteomics. 2014 Nov;14(21-22):2614-22 - PubMed
  106. Biomaterials. 2015 Sep;62:35-46 - PubMed
  107. J Control Release. 2012 May 10;159(3):429-34 - PubMed
  108. Cell Death Dis. 2014 Oct 02;5:e1435 - PubMed

Publication Types